

## EDO-S101

## Chemical Properties

CAS No. : 1236199-60-2

Formula: C<sub>19</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>


Molecular Weight: 415.36

Appearance: no data available

Storage:

store at low temperature, keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year



## Biological Description

|                            |  |
|----------------------------|--|
| Description                | EDO-S101 (Tinostamustine) is a pan HDAC inhibitor with IC <sub>50</sub> values of 9, 9 and 25 nM for HDAC1, HDAC2 and HDAC3, respectively.   |
| Targets(IC <sub>50</sub> ) | HDAC   |
| In vitro                   | EDOS101 inhibits HDAC activity in rat peripheral blood mononuclear cells (PBMCs) in a cellular assay by approximately 90% one hour after dosing with 10 mg/kg i.v. HDAC inhibition in PBMCs could not be increased with higher doses up to 50 mg/kg. EDO-S101 triggers apoptosis and shows strong antitumor activity in HL60 and Daudi cells. Initial in vitro experiments in HL60 cells shows an activation of the intrinsic pathway of apoptosis with cleavage of caspases 3, 9 and PARP and a marked reduction of anti-apoptotic proteins XIAP and Mcl-1. |
| In vivo                    | Intracellular HDAC inhibition of EDO-S101, which occurs rapidly after dosing is at maximum activity already at the lowest dose of 10 mg/kg and lasts for about 12-16 hours. Exposure to EDO-S101 causes a strong DNA repair response evidenced by activation of p53 and p21 in tumors taken from mice bearing subcutaneous human Burkitt's lymphoma. Tumors of BL rapidly shrink or are completely eradicated after i.v. administration of EDO-S101.   |
| Kinase Assay               | EDO-S101 is dissolved in DMSO and added to the assay buffer solution. EDO-S101 dilutions of 5 µL of each dilution is added to 50 µL of the reaction mixture including the Fluor de Lys substrate and all of the enzymatic reactions are conducted in duplicate at 37°C for 30 minutes. After enzymatic reactions, 50 µL of 2xHDAC developer is added to each well and fluorescence intensity is measured[1].   |

## Solubility Information

|            |  |
|------------|--|
| Solubility | DMSO: 30 mg/mL (72.23 mM), Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

## A DRUG SCREENING EXPERT

### Preparing Stock Solutions

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 2.4076 mL | 12.0378 mL | 24.0755 mL |
| 5 mM  | 0.4815 mL | 2.4076 mL  | 4.8151 mL  |
| 10 mM | 0.2408 mL | 1.2038 mL  | 2.4076 mL  |
| 50 mM | 0.0482 mL | 0.2408 mL  | 0.4815 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Mehrling T, et al. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. Anticancer Agents Med Chem. 2016;16(1):20-8.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481